UBS cuts Cytokinetics to neutral, sees takeout valuation at $105
https://seekingalpha.com/news/4057887-ubs-cuts-cytokinetics-to-neutral-sees-takeout-valuation-at-105?source=feed_sector_healthcare
Jan 24, 2024 - UBS has downgraded Cytokinetics (CYTK) to neutral, commenting that it believes some of the potential M&A premium has already been baked into the stock’s price. Read more here.
0
UBS Group: Upside Depends On Growing Book Value
https://seekingalpha.com/article/4665637-ubs-group-upside-depends-on-growing-book-value?source=feed_tag_editors_picks
Jan 28, 2024 - UBS Group AG is the last major Swiss bank after acquiring Credit Suisse for $3 billion in 2023. See why I rate UBS stock as a hold for now.
0
UBS reports mixed Q4 results; confirms financial targets, reinstates share buyback in 2H24
https://seekingalpha.com/news/4062951-ubs-gaap-eps-of--009-misses-by-242-revenue-of-1086b-beats-by-90m?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Feb 05, 2024 - UBS (UBS) reports 4Q/FY23 results and confirms financial targets, plans to propose $0.70 dividend per share, +27% Y/Y, and to reinstate share repurchases in 2H24.
Q4 GAAP EPS of -$0.09 mi..
0
Gold prices to hit $2,200 and silver could 'really shine' this year, UBS says
https://seekingalpha.com/news/4062949-gold-prices-to-hit-2200-and-silver-could-really-shine-this-year-ubs-says?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Feb 05, 2024 - Gold and silver prices are expected to rise further in 2024 as the Federal Reserve eventually will start cutting interest rate, UBS precious metals strategist Joni teves says.
0
UBS beats earnings expectations, announces up to $1 billion share buyback
https://www.cnbc.com/2024/02/06/ubs-beats-earnings-expectations-announces-up-to-1-billion-share-buyback.html
Feb 06, 2024 - Swiss banking giant UBS on Tuesday narrowly beat fourth-quarter earnings expectations and announced that it would recommence share buybacks worth $1 billion in the second half of the year.
0
UBS starts Biohaven at buy, cites diverse pipeline
https://seekingalpha.com/news/4064106-ubs-starts-biohaven-at-buy-cites-diverse-pipeline?source=feed_sector_healthcare
Feb 07, 2024 - UBS has initiated coverage of Biohaven (BHVN) with a buy rating, citing its attractive valuation and diverse pipeline. The investment bank said it was “bullish
0
UBS cuts BioXcel to neutral; cites regulatory issues, financing
https://seekingalpha.com/news/4069650-ubs-cuts-bioxcel-to-neutral-cites-regulatory-issues-financing?source=feed_sector_healthcare
Feb 21, 2024 - UBS has downgraded BioXcel Therapeutics (BTAI) to neutral, citing too much uncertainty about the company’s financing, regulatory alignment with the FDA, and end
0
UBS Group AG (UBS) Aided by Strategic Buyouts Amid High Costs
https://www.zacks.com/stock/news/2232509/ubs-group-ag-ubs-aided-by-strategic-buyouts-amid-high-costs?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2232509
Feb 27, 2024 - Business restructuring plans and strategic acquisitions support UBS Group AG's (UBS) financials. However, rising costs will likely limit bottom-line growth.
0
UBS (UBS) Up 5% Since Last Earnings Report: Can It Continue?
https://www.zacks.com/stock/news/2237436/ubs-ubs-up-5-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2237436
Mar 07, 2024 - UBS (UBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates
https://seekingalpha.com/news/4079564-ubs-sees-lilly-glp-1sleep-apnea-study-falling-short-of-street-estimates?source=feed_sector_healthcare
Mar 14, 2024 - UBS said it believes that upcoming data for Eli Lilly’s (LLY) GLP-1 drug tirzepatide in the treatment of sleep apnea will come in below Street expectations. Read more here.
0
Page 1>